You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer

Article info

Article menu
Basic tumor immunology
Original research
An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer

Authors

  • Nicole L Wittwer Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, AustraliaAdelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Alexander H Staudacher Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, AustraliaAdelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Vasilios Liapis Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, AustraliaAdelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Pina Cardarelli GPCR Therapeutics USA, Redwood City, California, USA PubMed articlesGoogle scholar articles
  • Harriet Warren Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Michael P Brown Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles

Citation

Wittwer NL, Staudacher AH, Liapis V, et al
An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
Journal for ImmunoTherapy of Cancer 2023;11:e006274. doi: 10.1136/jitc-2022-006274
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.